Vasomedical Announces Relocation of Corporate Office

WESTBURY, NY / ACCESSWIRE / September 25, 2015 / Vasomedical, Inc. (“Vasomedical”) (PINKSHEETS: VASO) today announced the relocation of its corporate office, effective Monday, September 28, 2015, to 137 Commercial Street, Plainview, NY 11803. In addition to the headquarters, this facility at Plainview, Long Island will also house the operations of Vasomedical Solutions, Inc. and the New York offices of NetWolves Network Services, both of which are wholly owned subsidiaries of Vasomedical, Inc.

The relocation takes places upon the expiration of the lease of the Company’s Westbury, NY facility, which has housed the Company’s headquarters and main operations for the last twenty years. The consolidated use of the new facility, together with the reduced need for space as the Company’s EECP(R) systems manufacturing has been transferred to its subsidiary located in China, results in improved operational efficiency and significant cost savings.

All communications to Vasomedical, Inc. as well as to Vasomedical Solutions and NetWolves Network Services New York offices should be addressed to 137 Commercial Street, Suite 200, Plainview, NY 11803, USA.

About Vasomedical

Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products and healthcare software solutions as well as in the provision of managed network services. The Company conducts its business through four wholly owned subsidiaries as follows. Vaso Diagnostics, Inc. d.b.a. VasoHealthcare provides professional sales services and is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Vaso Technology, Inc. provides network and IT services through two business units: VasoHealthcare IT Corp., a national value added reseller of GE Healthcare IT’s Radiology PACS (Picture Archiving and Communication System) software solutions and related services, including implementation, management and support, and NetWolves Network Services LLC, a managed network services provider with an extensive, proprietary service platform to a broad base of customers. Vasomedical Solutions, Inc. manages and coordinates the design, manufacture and sales of EECP(R) Therapy systems and other medical equipment operations. Vasomedical Global Corp. operates the Company’s China-based subsidiaries. Additional information is available on the Company’s website at www.vasomedical.com.

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreements; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

Investor Contacts:

Michael J. Beecher / Amanda Jiang
Investor Relations
Phone: 516-508-5840
Email:
 mbeecher@vasomedical.com / ajiang@vasomedical.com

SOURCE: Vasomedical, Inc.

ReleaseID: 432212